However, gene analysis showed that only 6% of ER+/HER2− ABC harbored FAT1 loss-of-function mutations in their metastatic tumors after treatment with CDK4/6i [30], likely representing a small population of patients with resistance to CDK4/6i, and the predictive value FAT1 mutations remain unclear. This evidence concerns the gene CDK4 and metastatic neoplasm.